New hope for advanced breast cancer: experimental combo enters human testing
NCT ID NCT05266105
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 20 times
Summary
This early-phase study tests a new drug, OP-1250, combined with the approved drug palbociclib in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and check for side effects, while also seeing if the combination can shrink tumors. Participants must have cancer that has spread and not received certain recent treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Waratah, New South Wales, 2298, Australia
-
Clinical Trial Site
Westmead, New South Wales, 2145, Australia
-
Clinical Trial Site
South Brisbane, Queensland, 4101, Australia
-
Clinical Trial Site
Southport, Queensland, 4215, Australia
-
Clinical Trial Site
Clayton, Victoria, 3168, Australia
-
Clinical Trial Site
Frankston, Victoria, 3199, Australia
-
Clinical Trial Site
Geelong, Victoria, 3220, Australia
-
Clinical Trial Site
Nedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.